ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.

ABSTRACT:

Background

Small cell lung cancer (SCLC) is a more aggressive subtype of lung cancer that often results in rapid tumor growth, early metastasis, and acquired therapeutic resistance. Consequently, such phenotypical characteristics of SCLC set limitations on viable procedural options, making it difficult to develop both screenings and effective treatments. In this study, we examine a novel mechanistic insight in SCLC cells that could potentially provide a more sensitive therapeutic alternative for SCLC patients.

Methods

Biochemistry studies, including size exclusion chromatography, mass spectrometry, and western blot analysis, were conducted to determine the protein-protein interaction between additional sex combs-like protein 3 (ASXL3) and bromodomain-containing protein 4 (BR

SUBMITTER: Szczepanski AP 

PROVIDER: S-EPMC7362484 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature